CSL Limited
Search results
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
CSL Behring provides a wide range of treatments for people with rare or life-threatening illnesses. Warm Greetings from Singapore! Welcome to CSL Behring Asia South! Based in Singapore, we are the hub of our commercial operations in South East Asia and Indian Subcontinent – a region we collectively call Asia South.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
The company is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004.
In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in our industry.
CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases.
CSL Behring is a specialty biotherapeutics company built on more than a century of service to people with serious medical conditions around the world. Biotherapies differ from conventional chemical-based pharmaceuticals in that they derive from human blood plasma or are manufactured using recombinant technologies.
Jun 20, 2023 · KING OF PRUSSIA, Pa., June 20, 2023 / PRNewswire / -- Global biotechnology leader CSL Behring today announced that the first patient has received U.S. Food and Drug Administration (FDA) approved HEMGENIX ® (etranacogene dezaparvovec-drlb) for hemophilia B in the United States.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry. CSL Behring: Rare & Serious Diseases Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine companies.
CSL Behring has locations to serve patients around the globe.
